A Randomized, Double-blind, 104-weeks Treatment Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Telbivudine Oral Solution and Tablets in Children and Adolescents With Compensated HBeAg-positive and Negative Chronic Hepatitis B Virus Infection
Phase of Trial: Phase III
Latest Information Update: 11 Sep 2019
Price : $35 *
At a glance
- Drugs Telbivudine (Primary)
- Indications Hepatitis B
- Focus Registrational; Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 20 Aug 2019 Status changed from completed to discontinued.
- 30 Jun 2019 Trial has been discontinued in UK, according to European Clinical Trials Database record.
- 30 May 2019 This trial has been completed in Greece, according to European Clinical Trials Database.